MedTrace Logo

Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors

NCT02342158 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2026-04-21

No results posted yet for this study

Summary

PERMED01 is a prospective monocenter clinical trial which aims to evaluate the number patients with locally advanced or metastatic cancer for whom identification of molecular alterations in tumor samples can lead to the delivery of a targeted therapy. PERMED01 will enroll 460 patients in 3 years.

Conditions

  • Neoplasm Metastasis

Interventions

PROCEDURE

biopsy or surgical sampling

OTHER

blood sampling

Sponsors & Collaborators

  • Cancer Research Center of Marseille

    collaborator OTHER

  • Institut Paoli-Calmettes

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-12
Primary Completion
2022-08-18
Completion
2022-08-18

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02342158 on ClinicalTrials.gov